HISA: Key Regulator of Immune System and Potential Drug Target

Target Name: HISLA

NCBI ID: G283587

HISLA

Other Name(s): LINC01146 | HIF1A stabilizing long noncoding RNA

HISA: Key Regulator of Immune System and Potential Drug Target

Human immune system-associated protein (HISA) is a key regulator of immune responses and plays a crucial role in maintaining the balance between the immune system and the body's tissues. The protein is also known as LINC01146, which is a key regulator of the immune response and has been identified as a potential drug target in the field of immunology.

HISA is a transmembrane protein that is expressed in a variety of tissues throughout the body, including the liver, spleen, and lymphoid organs. It is a key regulator of the immune response, and its dysfunction has been implicated in a number of diseases, including autoimmune diseases, cancer, and neurodegenerative diseases.

One of the key functions of HISA is its role in regulating the production and activation of T cells, which are a critical component of the immune system. T cells are responsible for cell-mediated immunity, and their activation and proliferation are critical for the development of many diseases. HISA has been shown to play a key role in regulating the production and activation of T cells, and its dysfunction has been implicated in a number of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Another key function of HISA is its role in regulating the production and activation of B cells, which are responsible for producing antibodies as part of the immune response. B cells are an important part of the immune system and play a critical role in the development of many diseases, including cancer. HISA has been shown to play a key role in regulating the production and activation of B cells, and its dysfunction has been implicated in a number of diseases, including leukemia and lymphoma.

In addition to its role in regulating T and B cell responses, HISA is also involved in regulating the production and function of natural killer cells, which are a critical part of the immune system. Natural killer cells are responsible for detecting and destroying infected or abnormal cells in the body, and their dysfunction has been implicated in a number of diseases, including cancer. HISA has been shown to play a key role in regulating the production and function of natural killer cells, and its dysfunction has been implicated in a number of diseases, including cancer.

Despite the importance of HISA in the immune system, its dysfunction has been implicated in a number of diseases, including autoimmune diseases, cancer, and neurodegenerative diseases. For example, studies have shown that HISA dysfunction is associated with an increased risk of developing rheumatoid arthritis, lupus, and multiple sclerosis. In addition, HISA has also been implicated in the development of certain cancers, including breast and ovarian cancer.

In conclusion, HISA is a key regulator of the immune system and its dysfunction has been implicated in a number of diseases. Its role in regulating the production and activation of T and B cells, as well as natural killer cells, makes it an attractive target for drug development. Further research is needed to fully understand the functions of HISA and its potential as a drug target.

Protein Name: HIF1A Stabilizing Long Noncoding RNA

The "HISLA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HISLA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets